{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:03:50Z","timestamp":1779800630399,"version":"3.53.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in four adults globally, yet early diagnosis remains challenging due to the limitations of current diagnostic modalities. While liver biopsy is the reference standard, its invasiveness limits its utility for population screening. Similarly, single-modality noninvasive tests often fail to distinguish inflammation from fibrosis or detect early metabolic injury. This review synthesized recent evidence (2020\u20132025) regarding the integration of serum metabolomic profiling with quantitative magnetic resonance imaging (MRI) biomarkers to enhance diagnostic precision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Emerging data indicate that serum metabolite panels, which detect upstream metabolic dysregulation, are highly complementary to MRI-PDFF (steatosis quantification) and MR Elastography (stiffness\/fibrosis measurement). Integrated panels have demonstrated Area Under the Receiver Operating Characteristic (AUROC) values exceeding 0.90 for detecting advanced fibrosis, outperforming individual methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We propose a three-tier clinical framework for integrating these biomarkers: transitioning from simplified biochemical screening in primary care to comprehensive multimodal staging in specialist centers, followed by risk-adapted longitudinal monitoring. This integrated approach offers a pathway toward precision hepatology, enabling earlier intervention and more accurate disease tracking without reliance on invasive procedures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00261-026-05573-3","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:19:17Z","timestamp":1779790757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated serum metabolomics and MRI biomarkers for MASLD: a practical framework for noninvasive staging and monitoring"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-6752","authenticated-orcid":false,"given":"Hamzah M.","family":"Alghzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhobi","family":"Mwita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Gundapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyant","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"1","key":"5573_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40842-024-00187-4","volume":"10","author":"B Basil","year":"2024","unstructured":"Basil, B., et al., From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome \u2013 current insights and future directions. Clinical Diabetes and Endocrinology, 2024. 10(1): p. 39.","journal-title":"Clinical Diabetes and Endocrinology"},{"issue":"23","key":"5573_CR2","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.3390\/ijms252312809","volume":"25","author":"D Beyo\u011flu","year":"2024","unstructured":"Beyo\u011flu, D., Y.V. Popov, and J.R. Idle, Metabolomic hallmarks of obesity and metabolic dysfunction-associated steatotic liver disease. International Journal of Molecular Sciences, 2024. 25(23): p. 12809.","journal-title":"International Journal of Molecular Sciences"},{"key":"5573_CR3","doi-asserted-by":"publisher","first-page":"1513598","DOI":"10.3389\/fmed.2025.1513598","volume":"12","author":"R Hernandez","year":"2025","unstructured":"Hernandez, R., et al., The hepatocellular model of fatty liver disease: From current imaging diagnostics to innovative proteomics technologies. Frontiers in Medicine, 2025. 12: p. 1513598.","journal-title":"Frontiers in Medicine"},{"issue":"12","key":"5573_CR4","doi-asserted-by":"publisher","first-page":"101853","DOI":"10.1016\/j.xcrm.2024.101853","volume":"5","author":"EY Tan","year":"2024","unstructured":"Tan, E.Y., M.D. Muthiah, and A.J. Sanyal, Metabolomics at the cutting edge of risk prediction of MASLD. Cell Reports Medicine, 2024. 5(12): p. 101853.","journal-title":"Cell Reports Medicine"},{"issue":"8","key":"5573_CR5","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/jcm14082750","volume":"14","author":"M Pecani","year":"2025","unstructured":"Pecani, M., et al., Metabolic syndrome and liver disease: Re-appraisal of screening, diagnosis, and treatment through the paradigm shift from NAFLD to MASLD. Journal of Clinical Medicine, 2025. 14(8): p. 2750.","journal-title":"Journal of Clinical Medicine"},{"issue":"8","key":"5573_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S2468-1253(22)00020-6","volume":"7","author":"KWM Abeysekera","year":"2022","unstructured":"Abeysekera, K.W.M., et al., Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review. The Lancet Gastroenterology & Hepatology, 2022. 7(8): p. 770\u2013780.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"3","key":"5573_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan, W.K., et al., Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Journal of Obesity & Metabolic Syndrome, 2023. 32(3): p. 197\u2013213.","journal-title":"Journal of Obesity & Metabolic Syndrome"},{"issue":"2","key":"5573_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cld.2023.01.020","volume":"27","author":"W Dunn","year":"2023","unstructured":"Dunn, W., L. Castera, and R. Loomba, Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2023. 27(2): p. 363\u2013372.","journal-title":"Clinics in Liver Disease"},{"issue":"2","key":"5573_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/biomedicines13020359","volume":"13","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee, S. and S.S. Im, Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus. Biomedicines, 2025. 13(2): p. 359.","journal-title":"Biomedicines"},{"key":"5573_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12967-025-06490-7","volume":"23","author":"W Zhang","year":"2025","unstructured":"Zhang, W., et al., Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learning. Journal of Translational Medicine, 2025. 23: p. 472.","journal-title":"Journal of Translational Medicine"},{"issue":"3","key":"5573_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","volume":"13","author":"F Abdelhameed","year":"2024","unstructured":"Abdelhameed, F., et al., Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Current Obesity Reports, 2024. 13(3): p. 510\u2013531.","journal-title":"Current Obesity Reports"},{"key":"5573_CR12","doi-asserted-by":"publisher","first-page":"117918","DOI":"10.1016\/j.trac.2024.117918","volume":"180","author":"D Cochran","year":"2024","unstructured":"Cochran, D., et al., A Reproducibility Crisis for Clinical Metabolomics Studies. Trends in Analytical Chemistry, 2024. 180: p. 117918.","journal-title":"Trends in Analytical Chemistry"},{"key":"5573_CR13","doi-asserted-by":"crossref","unstructured":"Sun, J. and Y. Xia, Pretreating and normalizing metabolomics data for statistical analysis. Genes & Diseases, 2024. 11(3): p. 100979.","DOI":"10.1016\/j.gendis.2023.04.018"},{"issue":"11","key":"5573_CR14","doi-asserted-by":"publisher","first-page":"e0298","DOI":"10.1097\/HC9.0000000000000298","volume":"7","author":"J Bai","year":"2023","unstructured":"Bai, J., et al., Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD. Hepatology Communications, 2023. 7(11): p. e0298.","journal-title":"Hepatology Communications"},{"issue":"Suppl 1","key":"5573_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/cts.2024.405","volume":"8","author":"M Brown","year":"2024","unstructured":"Brown, M., et al., Magnetic Resonance Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical and Translational Science, 2024. 8(Suppl 1): p. 141.","journal-title":"Journal of Clinical and Translational Science"},{"issue":"2","key":"5573_CR16","doi-asserted-by":"publisher","first-page":"e145-e148","DOI":"10.3350\/cmh.2024.0921","volume":"31","author":"L Guan","year":"2025","unstructured":"Guan, L., et al., Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on \u201cEpidemiology of metabolic dysfunction-associated steatotic liver disease\u201d. Clinical and Molecular Hepatology, 2025. 31(2): p. e145-e148.","journal-title":"Clinical and Molecular Hepatology"},{"key":"5573_CR17","doi-asserted-by":"publisher","first-page":"204201882513216","DOI":"10.1177\/20420188251321602","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y., et al., Clinical and pathological characteristics of metabolic dysfunction-associated steatotic liver disease and the key role of epigenetic regulation: implications for molecular mechanism and treatment. Therapeutic Advances in Endocrinology and Metabolism, 2025. 16: p. 20420188251321602.","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"issue":"3","key":"5573_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the, L","year":"2024","unstructured":"European Association for the Study of the, L., D. European Association for the Study of, and O. European Association for the Study of, EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 2024. 81(3): p. 492\u2013542.","journal-title":"Journal of Hepatology"},{"issue":"3","key":"5573_CR19","doi-asserted-by":"publisher","first-page":"e0375","DOI":"10.1097\/HC9.0000000000000375","volume":"8","author":"HE Huneault","year":"2024","unstructured":"Huneault, H.E., et al., Validation of a screening panel for pediatric metabolic dysfunction\u2013associated steatotic liver disease using metabolomics. Hepatology Communications, 2024. 8(3): p. e0375.","journal-title":"Hepatology Communications"},{"issue":"8","key":"5573_CR20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/life15081306","volume":"15","author":"F Jamal","year":"2025","unstructured":"Jamal, F., et al., Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Life, 2025. 15(8): p. 1306.","journal-title":"Life"},{"issue":"1","key":"5573_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling, R.K., et al., AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology, 2025. 81(1): p. 321\u2013357.","journal-title":"Hepatology"},{"issue":"18","key":"5573_CR22","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/nu16183061","volume":"16","author":"H Yuan","year":"2024","unstructured":"Yuan, H., et al., Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics. Nutrients, 2024. 16(18): p. 3061.","journal-title":"Nutrients"},{"key":"5573_CR23","unstructured":"Alkhouri, N. and M. Noureddin, Management Strategies for Metabolic Dysfunction--Associated Steatotic Liver Disease (MASLD). American Journal of Managed Care, 2024."},{"key":"5573_CR24","doi-asserted-by":"publisher","first-page":"1499013","DOI":"10.3389\/fmed.2024.1499013","volume":"11","author":"S Dawod","year":"2024","unstructured":"Dawod, S. and K. Brown, Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Frontiers in Medicine, 2024. 11: p. 1499013.","journal-title":"Frontiers in Medicine"},{"key":"5573_CR25","unstructured":"Girish, V. and S. John, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), in StatPearls. 2025, StatPearls Publishing."},{"key":"5573_CR26","doi-asserted-by":"publisher","first-page":"175628482412763","DOI":"10.1177\/17562848241276334","volume":"17","author":"D Hudson","year":"2024","unstructured":"Hudson, D., et al., Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques. Therapeutic Advances in Gastroenterology, 2024. 17: p. 17562848241276334.","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"2","key":"5573_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida, Y., A. Nakajima, and Y. Itoh, Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2014. 20(2): p. 475\u2013485.","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"5573_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3138\/canlivj-2021-0019","volume":"5","author":"F Zhou","year":"2022","unstructured":"Zhou, F., A. Stueck, and M. McLeod, Liver biopsy complication rates in patients with non-alcoholic fatty liver disease. Canadian Liver Journal, 2022. 5(2): p. 106\u2013112.","journal-title":"Canadian Liver Journal"},{"issue":"3","key":"5573_CR29","doi-asserted-by":"publisher","first-page":"e0318557","DOI":"10.1371\/journal.pone.0318557","volume":"20","author":"L Bertran","year":"2025","unstructured":"Bertran, L., et al., Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity. PLoS ONE, 2025. 20(3): p. e0318557.","journal-title":"PLoS ONE"},{"issue":"1","key":"5573_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12876-025-03625-4","volume":"25","author":"X Qiu","year":"2025","unstructured":"Qiu, X., et al., Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017-2020. BMC Gastroenterology, 2025. 25(1): p. 42.","journal-title":"BMC Gastroenterology"},{"issue":"3","key":"5573_CR31","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/hep.30163","volume":"69","author":"SJ Daniels","year":"2019","unstructured":"Daniels, S.J., et al., ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology, 2019. 69(3): p. 1075\u20131086.","journal-title":"Hepatology"},{"issue":"2","key":"5573_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang, D.Q., et al., Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology, 2023. 165(2): p. 463\u2013472.","journal-title":"Gastroenterology"},{"issue":"1","key":"5573_CR33","first-page":"33","volume":"5","author":"N Sariyar","year":"2024","unstructured":"Sariyar, N., et al., Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study. Hepatology Forum, 2024. 5(1): p. 33\u201336.","journal-title":"Hepatology Forum"},{"issue":"4","key":"5573_CR34","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj, E.A., et al., Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021. 75(4): p. 770\u2013785.","journal-title":"Journal of Hepatology"},{"key":"5573_CR35","doi-asserted-by":"crossref","unstructured":"Ratziu, V., et al., Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort. Gut, 2025.","DOI":"10.1136\/gutjnl-2025-335598"},{"key":"5573_CR36","doi-asserted-by":"crossref","unstructured":"Cheung, C.Y.Y., et al., Development and clinical validation of a novel protein biomarkers-based algorithm for risk prediction and diagnosis of advanced liver fibrosis: a multi-centre study. Journal of Advanced Research, 2025.","DOI":"10.1016\/j.jare.2025.09.033"},{"issue":"2","key":"5573_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/biom15020255","volume":"15","author":"MB Kj\u00e6r","year":"2025","unstructured":"Kj\u00e6r, M.B., et al., Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels. Biomolecules, 2025. 15(2): p. 255.","journal-title":"Biomolecules"},{"issue":"17","key":"5573_CR38","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.3390\/jcm14176148","volume":"14","author":"K Iwaszko-Sochal","year":"2025","unstructured":"Iwaszko-Sochal, K., B. Kasztelan-Szczerbi\u0144ska, and H. Cicho\u017a-Lach, Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD. Journal of Clinical Medicine, 2025. 14(17): p. 6148.","journal-title":"Journal of Clinical Medicine"},{"key":"5573_CR39","doi-asserted-by":"publisher","first-page":"1539708","DOI":"10.3389\/fmed.2025.1539708","volume":"12","author":"X Cao","year":"2025","unstructured":"Cao, X., et al., Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors. Frontiers in Medicine, 2025. 12: p. 1539708.","journal-title":"Frontiers in Medicine"},{"issue":"10","key":"5573_CR40","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.jlr.2024.100647","volume":"65","author":"O Quehenberger","year":"2024","unstructured":"Quehenberger, O., et al., Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease. Journal of Lipid Research, 2024. 65(10): p. 100647.","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"5573_CR41","doi-asserted-by":"publisher","first-page":"32328","DOI":"10.1038\/s41598-025-18172-x","volume":"15","author":"S Zampieri","year":"2025","unstructured":"Zampieri, S., et al., A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling. Scientific Reports, 2025. 15(1): p. 32328.","journal-title":"Scientific Reports"},{"key":"5573_CR42","doi-asserted-by":"crossref","unstructured":"Wilson, M.P., et al., Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD. Canadian Association of Radiologists Journal, 2025.","DOI":"10.1177\/08465371251357447"},{"issue":"5","key":"5573_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/apt.16513","volume":"54","author":"BS Madsen","year":"2021","unstructured":"Madsen, B.S., et al., PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease. Alimentary Pharmacology & Therapeutics, 2021. 54(5): p. 699\u2013708.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8","key":"5573_CR44","doi-asserted-by":"publisher","first-page":"100845","DOI":"10.1016\/j.jlr.2025.100845","volume":"66","author":"RB Pebriana","year":"2025","unstructured":"Pebriana, R.B., et al., Non-invasive identification of steatohepatitis in patients with MASLD using a sterol and lipidomic signature. Journal of Lipid Research, 2025. 66(8): p. 100845.","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"5573_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12876-024-03449-8","volume":"24","author":"A Yang","year":"2024","unstructured":"Yang, A., et al., Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study. BMC Gastroenterology, 2024. 24(1): p. 365.","journal-title":"BMC Gastroenterology"},{"key":"5573_CR46","doi-asserted-by":"crossref","unstructured":"Stefanakis, K., et al., Accurate Machine Learning-Based Diagnosis of At-Risk MASH and MASLD Subtypes Using Categorical Gradient Boosting and Select Clinical, Biochemical, and Metabolomic Measurements: Building Highly Robust Models With Few Variables Through a Multinational, Multi-Center, Biopsy-Proven Cohort. Journal of the Endocrine Society, 2024. 8(Suppl 1): p. bvae163.549.","DOI":"10.1210\/jendso\/bvae163.549"},{"key":"5573_CR47","first-page":"S530-S531","volume":"82","author":"Z Younossi","year":"2025","unstructured":"Younossi, Z., et al., A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality. Journal of Hepatology, 2025. 82: p. S530-S531.","journal-title":"Journal of Hepatology"},{"issue":"5","key":"5573_CR48","doi-asserted-by":"publisher","first-page":"1017-1032.e2","DOI":"10.1053\/j.gastro.2025.02.044","volume":"169","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z.M., et al., Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology, 2025. 169(5): p. 1017-1032.e2.","journal-title":"Gastroenterology"},{"key":"5573_CR49","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","volume":"15","author":"L Verschuren","year":"2024","unstructured":"Verschuren, L., et al., Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nature Communications, 2024. 15: p. 4564.","journal-title":"Nature Communications"},{"issue":"9","key":"5573_CR50","first-page":"723","volume":"13","author":"F Gong","year":"2025","unstructured":"Gong, F., et al., Biomarker Discovery for Metabolic Dysfunction\u2013associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External Validation. Journal of Clinical and Translational Hepatology, 2025. 13(9): p. 723\u2013733.","journal-title":"Journal of Clinical and Translational Hepatology"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05573-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05573-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05573-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:13:46Z","timestamp":1779797626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05573-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":50,"alternative-id":["5573"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05573-3","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}